KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Other Non-Current Liabilities (2016 - 2025)

Gsk (GSK) has 7 years of Other Non-Current Liabilities data on record, last reported at $1.4 billion in Q4 2024.

  • For Q4 2024, Other Non-Current Liabilities rose 2.76% year-over-year to $1.4 billion; the TTM value through Dec 2024 reached $1.4 billion, up 2.76%, while the annual FY2024 figure was $1.4 billion, 2.12% up from the prior year.
  • Other Non-Current Liabilities reached $1.4 billion in Q4 2024 per GSK's latest filing, up from $1.4 billion in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $1.4 billion in Q4 2024 and bottomed at $1.1 billion in Q4 2022.
  • Average Other Non-Current Liabilities over 4 years is $1.3 billion, with a median of $1.3 billion recorded in 2021.
  • Peak YoY movement for Other Non-Current Liabilities: decreased 15.07% in 2022, then soared 30.3% in 2023.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $1.2 billion in 2021, then decreased by 15.07% to $1.1 billion in 2022, then skyrocketed by 30.3% to $1.4 billion in 2023, then increased by 2.76% to $1.4 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $1.4 billion in Q4 2024, $1.4 billion in Q4 2023, and $1.1 billion in Q4 2022.